Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment

Simple item page
dc.contributor.authorKittur, Farooqahmed S.en
dc.contributor.authorHung, Chiu-Yuehen
dc.contributor.authorLi, P. Andyen
dc.contributor.authorSane, David C.en
dc.contributor.authorXie, Jiahuaen
dc.date.accessioned2023-04-27T14:51:10Zen
dc.date.available2023-04-27T14:51:10Zen
dc.date.issued2023-04-18en
dc.date.updated2023-04-27T13:50:32Zen
dc.description.abstractNeuroprotective drugs to protect the brain against cerebral ischemia and reperfusion (I/R) injury are urgently needed. Mammalian cell-produced recombinant human erythropoietin (rhuEPO<sup>M</sup>) has been demonstrated to have excellent neuroprotective functions in preclinical studies, but its neuroprotective properties could not be consistently translated in clinical trials. The clinical failure of rhuEPO<sup>M</sup> was thought to be mainly due to its erythropoietic activity-associated side effects. To exploit its tissue-protective property, various EPO derivatives with tissue-protective function only have been developed. Among them, asialo-rhuEPO, lacking terminal sialic acid residues, was shown to be neuroprotective but non-erythropoietic. Asialo-rhuEPO can be prepared by enzymatic removal of sialic acid residues from rhuEPO<sup>M</sup> (asialo-rhuEPO<sup>E</sup>) or by expressing human <i>EPO</i> gene in glycoengineered transgenic plants (asialo-rhuEPO<sup>P</sup>). Both types of asialo-rhuEPO, like rhuEPO<sup>M</sup>, displayed excellent neuroprotective effects by regulating multiple cellular pathways in cerebral I/R animal models. In this review, we describe the structure and properties of EPO and asialo-rhuEPO, summarize the progress on neuroprotective studies of asialo-rhuEPO and rhuEPO<sup>M</sup>, discuss potential reasons for the clinical failure of rhuEPO<sup>M</sup> with acute ischemic stroke patients, and advocate future studies needed to develop asialo-rhuEPO as a multimodal neuroprotectant for ischemic stroke treatment.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationKittur, F.S.; Hung, C.-Y.; Li, P.A.; Sane, D.C.; Xie, J. Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment. Pharmaceuticals 2023, 16, 610.en
dc.identifier.doihttps://doi.org/10.3390/ph16040610en
dc.identifier.urihttp://hdl.handle.net/10919/114816en
dc.language.isoenen
dc.publisherMDPIen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectmultimodal neuroprotectanten
dc.subjecterythropoietinen
dc.subjecthematopoietic activityen
dc.subjectasialo-erythropoietinen
dc.subjectnon-erythropoiesisen
dc.subjecterythropoietin receptoren
dc.subjectcerebral ischemia and reperfusionen
dc.subjectpreclinical studyen
dc.subjectclinical trialen
dc.titleAsialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatmenten
dc.title.serialPharmaceuticsen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
pharmaceuticals-16-00610.pdf
Size:
2.62 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Journal Articles, Multidisciplinary Digital Publishing Institute (MDPI)
Scholarly Works, Virginia Tech Carilion School of Medicine (VTCSOM)